Application areas of modern automated methods of anti-Müllerian hormone evaluation

Literature review

Authors

DOI:

https://doi.org/10.18370/2309-4117.2021.59.85-91

Keywords:

premature menopause, ovarian reserve, granulosa cell tumors, polycystic ovary syndrome, functional hypothalamic amenorrhea, delayed sexual development

Abstract

Anti-Müllerian hormone (AMН) is a glycopeptide of the transforming growth factors β-family, used in many medical fields. Understanding of the biological role of AMH at norm and at pathology such as polycystic ovary syndrome (PCOS) is expanding. This review includes the literature analysis on the synthesis and biological role of AMH in women and men; factors influencing its level; possibilities and limitations of clinical use of AMH in pediatric endocrinology/urogynecology, reproductive medicine, diagnosis of PCOS and other dyshormonal conditions, oncofertility programs and diagnosis of genital tumors.
Effects of AMH in women: inhibiting the entry of primordial follicles into growth, control of follicle sensitivity to follicle-stimulating hormone, participation in the selection of the dominant
follicle, inhibition of aromatase activity in granulosa cells of the follicle, regulation of the gonadotropic generator of gonadotropic releasing hormone.
AMH is an important component of predicting the response to ovulation stimulation in infertile women, diagnosis of nonclassical forms of PCOS, premature ovarian failure to the development
of amenorrhea, other hormonal diseases, granulosa cell tumors, decisions about the possibility of maintaining reproductive function after cancer treatment. Currently, AMH cannot be used as
a tool for individualized prediction of the age of menopause, fertility. It is not recommended to decide on the use of cryotechnologies based only on the AMH level.
Evolution of laboratory estimation of АМН as an important factor of impact on clinical and scientific application of research is also considered. Despite significant improvements in the
technical characteristics of test systems for determining the AMH level, there are limitations in the use of this diagnostic marker due to the lack of standardization. This shortcoming can be
overcome by following principles: do not base important clinical decisions only at the AMH level, and use this indicator in conjunction with other laboratory parameters and clinical data;
adhere to the consistent use of one automated test system until the introduction of the standard in laboratory practice.

Author Biographies

O.A. Burka, Bogomolets National Medical University; “DILA” Medical Laboratory, Kyiv

PhD, associate professor at the Obstetrics and Gynaecology Department No. 1;

Scientific consultant

T.M. Tutchenko, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”; SSI “CIMT of the NAS of Ukraine»; “DILA” Medical Laboratory, Kyiv

PhD, senior researcher of the Endocrine Gynecology Department;

Department of Reproductive Health;

Scientific consultant

O.M. Kudlai, Military unit, Kyiv

PhD, obstetrician-gynecologist, head of the gynecological department

T.V. Shevchuk, Medical Club GRACE Clinic, Kyiv

PhD, endocrinologist-gynecologist

O.V. Protsenko, Regional Endocrinological Centre, Chernivtsi

Obstetrician gynecologist

O.M. Makarovets, Regional Perinatal Centre of Rivne City Council, Rivne

Obstetrician gynecologist

References

  1. Josso, N. “Professor Alfred Jost: The builder of modern sex differentiation.” Sex Dev 2 (2008): 55–63. DOI: 10.1159/000129690
  2. Josso, N. “Women in reproductive science Anti-Müllerian hormone: A look back and ahead.” Reproduction 158 (2019): F81–F89. DOI: 10.1530/REP-18-0602
  3. Xu, H., Zhang, M., Zhang, H., et al. “Clinical Applications of Serum Anti-Müllerian Hormone Measurements in Both Males and Females: An Update.” Innov States 2 (2021): 100091. DOI: 10.1016/j.xinn.2021.100091
  4. Sobel, V., Zhu, Y.S., Imperato-McGinley, J. “Fetal hormones and sexual differentiation.” Obstet Gynecol Clin North Am 31 (2004): 837–56. DOI: 10.1016/j.ogc.2004.08.005
  5. Mamsen, L.S., Ernst, E.H., Borup, R., et al. “Temporal expression pattern of genes during the period of sex differentiation in human embryonic gonads.” Sci Rep 7 (2017): 1–16. DOI: 10.1038/s41598-017-15931-3
  6. Xu, H.Y., Zhang, H.X., Xiao, Z., et al. “Regulation of anti-Müllerian hormone (AMH) in males and the associations of serum AMH with the disorders of male fertility.” Asian J Androl 21 (2019): 109–14. DOI: 10.4103/aja.aja_83_18
  7. Neto, F.T.L., Bach, P.V., Najari, B.B., et al. “Spermatogenesis in humans and its affecting factors.” Semin Cell Dev Biol 59 (2016): 10–26. DOI: 10.1016/j.semcdb.2016.04.009
  8. Goldberg, E., Zirkin, B.R. “Spermatogenesis: Overview.” In: Encycl. Reprod. Elsevier (2018): 13–8. DOI: 10.1016/B978-0-12-801238-3.64422-7
  9. Kelsey, T.W., Wright, P., Nelson, S.M., et al. “A validated model of serum Anti-Müllerian hormone from conception to menopause.” PLoS One 6 (2011): e22024. DOI: 10.1371/journal.pone.0022024
  10. Cui, L., Qin, Y., Gao, X., et al. “Antimüllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause.” Fertil Steril 105 (2016): 481–485.e1. DOI: 10.1016/j.fertnstert.2015.10.017
  11. Visser, J.A., de Jong, F.H., Laven, J.S.E., Themmen, A.P.N. “Anti-Müllerian hormone: A new marker for ovarian function.” Reproduction 131 (2006): 1–9. DOI: 10.1530/rep.1.00529
  12. Dewailly, D., Robin, G., Peigne, M., et al. “Interactions between androgens, FSH, anti-Mullerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary.” Hum Reprod Update 22 (2016): 709–24. DOI: 10.1093/humupd/dmw027
  13. Durlinger, A.L.L., Visser, J.A., Themmen, A.P.N. “Regulation of ovarian function: The role of anti-Müllerian hormone.” Reproduction 124 (2002): 601–9. DOI: 10.1530/rep.0.1240601
  14. Grynberg, M., Pierre, A., Rey, R., et al. “Differential regulation of ovarian anti-müllerian hormone (AMH) by estradiol through α- and β-estrogen receptors.” J Clin Endocrinol Metab 97 (2012). DOI: 10.1210/jc.2011-3133
  15. Grossman, M.P., Nakajima, S.T., Fallat, M.E., Siow, Y. “Müllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture.” Fertil Steril 89 (2008): 1364–70. DOI: 10.1016/j.fertnstert.2007.03.066
  16. Cimino, I., Casoni, F., Liu, X., et al. “Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion.” Nat Commun 7 (2016): 1–12. DOI: 10.1038/ncomms10055
  17. Yan, B. “Role of Anti-Müllerian Hormone (AMH) in Regulating Hypothalamus-Pituitary Function.” In: ACM Int. Conf. Proceeding Ser. Association for Computing Machinery (2020): 82–6. DOI: 10.1145/3444884.3444899
  18. Silva, M.S.B., Giacobini, P. “New insights into anti-Müllerian hormone role in the hypothalamic–pituitary–gonadal axis and neuroendocrine development.” Cell Mol Life Sci 78 (2021): 1–16. DOI: 10.1007/s00018-020-03576-x
  19. Gravholt, C.H., Andersen, N.H., Conway, G.S., et al. “Clinical practice guidelines for the care of girls and women with Turner syndrome: Proceedings from the 2016 Cincinnati International Turner Syndrome Meeting.” Eur J Endocrinol 177 (2017): G1–G70. DOI: 10.1530/EJE-17-0430
  20. Oktay, K., Bedoschi, G., Berkowitz, K., et al. “Fertility Preservation in Women with Turner Syndrome: A Comprehensive Review and Practical Guidelines.” J Pediatr Adolesc Gynecol 29 (2016): 409–16. DOI: 10.1016/j.jpag.2015.10.011
  21. Brambila-Tapia, A.J.L., Rivera, H., García-Castillo, H., et al. “47,XXX/45,X/46,XX mosaicism in a patient with Turner phenotype and spontaneous puberal development.” Fertil Steril 92 (2009): 1747.e5–1747.e7. DOI: 10.1016/j.fertnstert.2009.07.1008
  22. Webber, L., Davies, M., Anderson, R., et al. “ESHRE Guideline: management of women with premature ovarian insufficiency.” Hum Reprod 31 (2016): 926–37. DOI: 10.1093/humrep/dew027
  23. Oh, S.R., Choe, S.Y., Cho, Y.J. “Clinical application of serum anti-Müllerian hormone in women.” Clin Exp Reprod Med. 46 (2019): 50–9. DOI: 10.5653/cerm.2019.46.2.50
  24. Boehm, U., Bouloux, P.M., Dattani, M.T., et al. “Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment.” Nat Rev Endocrinol 11 (2015): 547–64. DOI: 10.1038/nrendo.2015.112
  25. Young, J., Xu, C., Papadakis, G.E., et al. “Clinical Management of Congenital Hypogonadotropic Hypogonadism.” Endocr Rev 40 (2019): 669–710. DOI: 10.1210/er.2018-00116
  26. Tian, Z., Zhang, Y., Zhang, C., et al. “Antral follicle count is reduced in the presence of endometriosis: a systematic review and meta-analysis.” Reprod Biomed Online 42 (2021): 237–47. DOI: 10.1016/j.rbmo.2020.09.014
  27. Kasapoglu, I., Ata, B., Uyaniklar, O., et al. “Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study.” Fertil Steril 110 (2018): 122–7. DOI: 10.1016/j.fertnstert.2018.03.015
  28. Younis, J.S., Nelson, S.M. “Does large endometrioma per se increase AMH level?” Reprod Biomed Online 42 (2021): 691–3. DOI: 10.1016/j.rbmo.2021.01.016
  29. Moslehi, N., Shab-Bidar, S., Ramezani Tehrani, F., et al. “Is ovarian reserve associated with body mass index and obesity in reproductive aged women? A meta-analysis.” Menopause 1 (2018). DOI: 10.1097/GME.0000000000001116.
  30. Moridi, I., Chen, A., Tal, O., Tal, R. “The association between vitamin d and anti-müllerian hormone: A systematic review and meta-analysis.” Nutrients 12 (2020): 1567. DOI: 10.3390/nu12061567
  31. Oktay, K., Harvey, B.E., Partridge, A.H., et al. “Fertility preservation in patients with cancer: ASCO clinical practice guideline update.” J Clin Oncol 36 (2018)}: 1994–2001. DOI: 10.1200/JCO.2018.78.1914
  32. Lambertini, M., Peccatori, F.A., Demeestere, I., et al. “Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines.” Ann Oncol 31 (2020): 1664–78. DOI: 10.1016/j.annonc.2020.09.006
  33. Ramezani Tehrani, F., Solaymani-Dodaran, M., Hedayati, M., Azizi, F. “Is polycystic ovary syndrome an exception for reproductive aging?” Hum Reprod 25 (2010): 1775–81. DOI: 10.1093/humrep/deq088
  34. Forslund, M., Landin-Wilhelmsen, K., Schmidt, J., et al. “Higher menopausal age but no differences in parity in women with polycystic ovary syndrome compared with controls.” Acta Obstet Gynecol Scand 98 (2019): 320–6. DOI: 10.1111/aogs.13489
  35. Minooee, S., Ramezani Tehrani, F., Rahmati, M., et al. “Prediction of age at menopause in women with polycystic ovary syndrome.” Climacteric 21 (2018): 29–34. DOI: 10.1080/13697137.2017.1392501
  36. Seifer, D.B., Merhi, Z. “Is AMH a regulator of follicular atresia?” J Assist Reprod Genet 31 (2014): 1403–7. DOI: 10.1007/s10815-014-0328-7
  37. Webber, L.J., Stubbs, S., Stark, J., et al. “Formation and early development of follicles in the polycystic ovary.” Lancet 362 (2003): 1017–21. DOI: 10.1016/S0140-6736(03)14410-8
  38. Makolle, S., Catteau-Jonard, S., Robin, G., Dewailly, D. “Revisiting the serum level of anti-Müllerian hormone in patients with functional hypothalamic anovulation.” Hum Reprod 36 (2021): 1043–51. DOI: 10.1093/humrep/deab024
  39. Robin, G., Gallo, C., Catteau-Jonard, S., et al. “Polycystic ovary-like abnormalities (PCO-L) in women with functional hypothalamic amenorrhea.” J Clin Endocrinol Metab 97 (2012): 4236–43. DOI: 10.1210/jc.2012-1836
  40. Alemyar, A., van der Kooi, A.L.L.F., Laven, J.S.E. “Anti-Müllerian hormone and ovarian morphology in women with hypothalamic hypogonadism.” J Clin Endocrinol Metab 105 (2020): e2008–e2014. DOI: 10.1210/clinem/dgaa116
  41. Carmina, E., Fruzzetti, F., Lobo, R.A. “Features of polycystic ovary syndrome (PCOS) in women with functional hypothalamic amenorrhea (FHA) may be reversible with recovery of menstrual function.” Gynecol Endocrinol 34 (2018): 301–4. DOI: 10.1080/09513590.2017.1395842
  42. Chun, S., Koo, Y.H., Na, Y.J. “Two Cases of Primary Ovarian Insufficiency Accompanied by High Serum Anti-Müllerian Hormone Levels and Preservation of Ovarian Follicles.” J Menopausal Med 26 (2020): 143. DOI: 10.6118/jmm.20004
  43. Pradervand, P.-A., Antaki, R., Phillips, S., et al. “Fertility Preservation in Premature Ovarian Insufficiency (POI) Secondary to FSH Receptor Gene (FSHR) Mutation: Is There a New Hope?” Case Reports Clin Med 06 (2017): 274–80. DOI: 10.4236/crcm.2017.610030
  44. Karkanaki, A., Vosnakis, C., Panidis, D. “The clinical significance of anti-müllerian hormone evaluation in gynecological endocrinology.” Hormones 10 (2011): 95–103. DOI: 10.14310/horm.2002.1299
  45. Rey, R.A., Lhomme, C., Marcillac, I., et al. “Antimullerian hormone as a serum marker of granulosa cell tumors of the ovary: Comparative study with serum α-inhibin and estradiol.” Am J Obstet Gynecol 174 (1996): 958–65. DOI: 10.1016/S0002-9378(96)70333-2
  46. Urrutia, M., Grinspon, R.P., Rey, R.A. “Comparing the role of anti-Müllerian hormone as a marker of FSH action in male and female fertility.” Expert Rev Endocrinol Metab 14 (2019): 203–14. DOI: 10.1080/17446651.2019.1590197
  47. Matuszczak, E., Hermanowicz, A., Komarowska, M., Debek, W. “Serum AMH in physiology and pathology of male gonads.” Int J Endocrinol 2013 (2013). DOI: 10.1155/2013/128907
  48. Tal, R., Seifer, D.B. “Ovarian reserve testing: a user’s guide.” Am J Obstet Gynecol 217 (2017): 129–40. DOI: 10.1016/j.ajog.2017.02.027
  49. Penzias, A., Azziz, R., Bendikson, K., et al. “Testing and interpreting measures of ovarian reserve: a committee opinion.” Fertil Steril 114 (2020): 1151–7. DOI: 10.1016/j.fertnstert.2020.09.134
  50. La Marca, A., Sighinolfi, G., Radi, D., et al. “Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).” Hum Reprod Update 16 (2009): 113–30. DOI: 10.1093/humupd/dmp036
  51. Li, H.W.R., Lee, V.C.Y., Lau, E.Y.L., et al. “Ovarian response and cumulative live birth rate of women undergoing in-vitro fertilisation who had discordant anti-mullerian hormone and antral follicle count measurements: A retrospective study.” PLoS One 9 (2014): e108493. DOI: 10.1371/journal.pone.0108493
  52. Bosch, E., Broer, S., Griesinger, G., et al. “ESHRE guideline: ovarian stimulation for IVF/ICSI.” Hum Reprod Open 2020 (2020): 1–13. DOI: 10.1093/hropen/hoaa009
  53. Steiner, A.Z., Pritchard, D., Stanczyk, F.Z., et al. “Association between biomarkers of ovarian reserve and infertility among older women of reproductive age.” JAMA 318 (2017): 1367–76. DOI: 10.1001/jama.2017.14588
  54. Ripley, M., Lanes, A., Léveillé, M.C., Shmorgun, D. “Does ovarian reserve predict egg quality in unstimulated therapeutic donor insemination cycles?” Fertil Steril 103 (2015): 1170–5.e2. DOI: 10.1016/j.fertnstert.2015.01.018
  55. Li, H.W.R., He, Y.L., Li, R., et al. “Age-specific reference ranges of serum anti-müllerian hormone in healthy women and its application in diagnosis of polycystic ovary syndrome: a population study.” BJOG An Int J Obstet Gynaecol 127 (2020): 720–8. DOI: 10.1111/1471-0528.16147
  56. Sova, H., Unkila-Kallio, L., Tiitinen, A., et al. “Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes.” Gynecol Endocrinol (2019): 1–6. DOI: 10.1080/09513590.2018.1559807
  57. Gilbert, E.W., Tay, C.T., Hiam, D.S., et al. “Comorbidities and complications of polycystic ovary syndrome: An overview of systematic reviews.” Clin Endocrinol (Oxf) 89 (2018): 683–99. DOI: 10.1111/cen.13828
  58. Teede, H., Misso, M., Tassone, E.C., et al. “Anti-Müllerian Hormone in PCOS: A Review Informing International Guidelines.” Trends Endocrinol Metab 30 (2019): 467–78. DOI: 10.1016/J.TEM.2019.04.006
  59. Capuzzo, M., La Marca, A. “Use of AMH in the Differential Diagnosis of Anovulatory Disorders Including PCOS.” Front Endocrinol (Lausanne) 11 (2021). DOI: 10.3389/fendo.2020.616766
  60. La Marca, A., Marzotti, S., Brozzetti, A., et al. “Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles.” J Clin Endocrinol Metab 94 (2009): 3816–23. DOI: 10.1210/jc.2009-0817
  61. Guzel, Y., Aba, Y.A., Yakin, K., Oktem, O. “Menstrual cycle characteristics of young females with occult primary ovarian insufficiency at initial diagnosis and one-year follow-up with serum AMH level and antral follicle count.” PLoS One 12 (2017). DOI: 10.1371/journal.pone.0188334
  62. Jiao, X., Meng, T., Zhai, Y., et al. “Ovarian Reserve Markers in Premature Ovarian Insufficiency: Within Different Clinical Stages and Different Etiologies.” Front Endocrinol (Lausanne) 12 (2021). DOI: 10.3389/fendo.2021.601752
  63. Anderson, R.A., Nelson, S.M. “Anti-Müllerian Hormone in the Diagnosis and Prediction of Premature Ovarian Insufficiency.” Semin Reprod Med 38 (2020): 263–9. DOI: 10.1055/s-0040-1722319
  64. Desongnis, S., Robin, G., Dewailly, D., et al. “AMH assessment five or more years after an initially low AMH level.” Eur J Obstet Gynecol Reprod Biol 256 (2021): 70–4. DOI: 10.1016/j.ejogrb.2020.10.053
  65. Depmann, M., Eijkemans, M.J.C., Broer, S.L., et al. “Does AMH relate to timing of menopause? results of an individual patient data meta-analysis.” J Clin Endocrinol Metab 103 (2018): 3593–600. DOI: 10.1210/jc.2018-00724
  66. Sonigo, C., Beau, I., Binart, N., Grynberg, M. “Anti-Müllerian Hormone in Fertility Preservation: Clinical and Therapeutic Applications.” Clin Med Insights Reprod Heal 13 (2019): 117955811985475. DOI: 10.1177/1179558119854755
  67. Chen, S., Yang, B., Fan, J. “Diagnostic value of Anti-Mullerian hormone in ovarian granulosa cell tumor: A meta-analysis.” Eur J Obstet Gynecol Reprod Biol 253 (2020): 266–72. DOI: 10.1016/j.ejogrb.2020.08.011
  68. Dridi, M., Chraiet, N., Batti, R., et al. “Granulosa Cell Tumor of the Ovary: A Retrospective Study of 31 Cases and a Review of the Literature.” Int J Surg Oncol 2018 (2018). DOI: 10.1155/2018/4547892
  69. Fauser, B.C.J.M., Nelson, S.M. “Next steps toward AMH as a robust biomarker for assessing ovarian aging in individual women.” J Clin Endocrinol Metab 105 (2020): 2643–4. DOI: 10.1210/clinem/dgaa220
  70. Bungum, L., Tagevi, J., Jokubkiene, L., et al. “The impact of the biological variability or assay performance on AMH measurements: A prospective cohort study with AMH tested on three analytical assay-platforms.” Front Endocrinol (Lausanne) 9 (2018): 1–10. DOI: 10.3389/fendo.2018.00603

Downloads

Published

2021-07-22

How to Cite

Burka, O., Tutchenko, T., Kudlai, O., Shevchuk, T., Protsenko, O., & Makarovets, O. (2021). Application areas of modern automated methods of anti-Müllerian hormone evaluation: Literature review. REPRODUCTIVE ENDOCRINOLOGY, (59), 85–91. https://doi.org/10.18370/2309-4117.2021.59.85-91

Issue

No. 59 (2021)

Section

Gynecology

License

Copyright (c) 2021 О.А. Бурка, Т.М. Тутченко, О.М. Кудлай, Т.В. Шевчук, О.В. Проценко, О.М. Макаровець

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.